Shots:
- Penn allied with Regeneron to investigate Ab cocktail (casirivimab & imdevimab) to prevent COVID-19 infection when delivering intranasally via AAV vectors
- The collaboration b/w Wilson and Penn’s GTP and Regeneron will have two phases. The first phase will include the validation of the effectiveness of Abs delivered via AAV in a large animal model challenge study. If successful, the research team will complete studies to support the filing of IND to the FDA
- Regeneron’s Ab cocktail (casirivimab & imdevimab) is studied in clinical trials for the prevention of COVID-19 and has received the US FDA’s EUA in certain high-risk patients with mild to mod. COVID-19
Click here to read full press release/ article | Ref: Penn Medicine | Image: LaingBuisson News
The post Regeneron Collaborates with Penn to Explore Intranasal Delivery of COVID-19 Ab Cocktail via Gene Therapy Platform first appeared on PharmaShots.
